Skip to main content
GutCited

Lactobacillus gasseri für Helicobacter pylori Infection

B

Three RCTs show L. gasseri LG21 suppresses H. pylori load and improves eradication rates when combined with standard triple therapy. Also improves GERD symptoms.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dh\u002Dpylori'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

Fazit

Three RCTs show L. gasseri LG21 suppresses H. pylori load and improves eradication rates when combined with standard triple therapy. Also improves GERD symptoms.

Key Study Findings

In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None vs.: H. pylori infection without lactobacilli Outcome: ADAM17, HBEGF, TGF-alpha expression Wirkung: None None

Population: AGS gastric epithelial cells and mouse model

In Vitro
Lactobacillus gasseri Suppresses the Helicobacter pylori-Induced Hummingbird Phenotype by Inhibiting CagA Phosphorylation and SHP-2 Interaction.
Dose: None vs.: CagA-expressing AGS cells without L. gasseri Outcome: Suppression of CagA phosphorylation (hummingbird) Wirkung: None None

Population: Human gastric AGS cell line with H. pylori CagA

In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml vs.: None Outcome: Inflammatory markers Wirkung: None None

Population: None

Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None vs.: None Outcome: Inflammatory markers Wirkung: None None

Population: Cancer patients

Other
Two novel lactic acid bacteria, Limosilactobacillus fermentum MN-LF23 and Lactobacillus gasseri MN-LG80, inhibited Helicobacter pylori …
Dose: None vs.: None Outcome: H. pylori abundance reduction Wirkung: None None

Population: H. pylori-infected C57BL/6 mice

Case-Control n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None vs.: None Outcome: Oral/gastric microbiome associations with IM Wirkung: None None

Population: Gastric intestinal metaplasia cases and matched controls

Key Statistics

3

Studien

350

Teilnehmer

Positive

B

Bewertung

Referenced Papers

International journal of … 2022 59 Zitierungen
Comparative immunology, microbiology … 2019 72 Zitierungen
Probiotics and antimicrobial … 2010 9 Zitierungen

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

general:
1-10 billion CFU/day
gerdsupport:
1-5 billion CFU/day
hpylorisupport:
100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks

Obergrenze: Well-tolerated up to 10 billion CFU/day in clinical trials

In der Forschung untersuchte Dosierungen

Dosierung Dauer Wirkung N
None -- Positive --
None -- Positive --
50 μg/ml -- Mixed --
None -- Positive --
None -- Positive --
None -- Neutral 178
None -- Positive --
1 g -- Positive --

Beste Einnahmezeit: Before meals or with meals; yogurt form taken with food

Safety & Side Effects

Gemeldete Nebenwirkungen

  • Mild gas during initial use
  • Occasional loose stools
  • Rare abdominal discomfort
  • Very rare: bacteremia in immunocompromised individuals

Bekannte Wechselwirkungen

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Proton pump inhibitors (altered gastric pH may affect colonization)
  • Immunosuppressants (theoretical risk in immunocompromised patients)

Tolerierbare Höchstaufnahmemenge: Well-tolerated up to 10 billion CFU/day in clinical trials

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Lactobacillus gasseri help with Helicobacter pylori Infection?
Based on 3 studies with 350 participants, there is moderate evidence from clinical studies that Lactobacillus gasseri may support Helicobacter pylori Infection management. Our evidence grade is B (Good Evidence).
How much Lactobacillus gasseri should I take for Helicobacter pylori Infection?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus gasseri?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus gasseri and Helicobacter pylori Infection?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.

Related Evidence

Andere Inhaltsstoffe für Helicobacter pylori Infection

Lactobacillus gasseri für andere Beschwerden

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.